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Editorial
Decreasing the duration of invasive mechanical venti-
lation by early safe extubation is a major clinical goal 
in intensive care unit (ICU) [1]. Prolonged intubation 
increases the risk of ventilator-induced lung injury, ven-
tilator-induced diaphragm dysfunction, myopathy and 
infections. Nonetheless, patients’ management in the 
post-extubation period can be challenging and every 
effort should be made to avoid re-intubation, which is 
associated with significantly increased morbidity and 
mortality [1].
To this end, in this issue of the “Annals of Intensive 
Care,” Dr. Fernandez and colleagues report findings from 
a randomized controlled trial comparing low-flow oxy-
gen supplied through nasal prongs or facial mask versus 
high-flow nasal cannula (HFNC) for 24 h after extubation 
as respiratory supports in patients at high risk of extuba-
tion failure [2]. This is the third large clinical trial recently 
published by the research group of Dr. Fernandez on the 
same topic, the other two being comparisons of HFNC 
versus noninvasive ventilation (NIV) in high-risk patients 
and of HFNC versus standard oxygen in low risk [3, 4]. 
In this issue study [2], patients’ population consisted of 
adult critically ill patients receiving mechanical ventila-
tion for more than 12 h, considered as high risk of extu-
bation failure and extubated after successful spontaneous 
breathing trial (SBT). High risk of extubation failure was 
defined as the presence of at least one among the follow-
ing: age above 65  years old, heart failure, moderate or 
severe chronic obstructive pulmonary disease, APACHE 
II score higher than 12, body mass index above 30  kg/
m2, weak cough with abundant secretions, more than one 
SBT failure and/or mechanical ventilation for more than 
7 days. The primary study outcome was the development 
of respiratory failure within 72  h after extubation, with 
an expected incidence of 28% in the conventional oxy-
gen group versus 21% in the HFNC group. Re-intubation, 
length of stay and mortality were secondary outcomes.
We must underline that the study has several limita-
tions, in part acknowledged by the authors. First, avoiding 
use of NIV in high-risk patients might pose serious ethical 
issues as it might be failure to apply a treatment that was 
clearly shown to improve clinical outcome [5]. Second, 
the planned sample size for the primary outcome was 
1184 patients (592 per arm), but the study was stopped at 
155 due to slow recruitment (average of 1.6 patients per 
unit per month). Third, it is questionable whether assess-
ment of the risk of extubation failure should be performed 
beforehand without any post-extubation reassessment: 
For example, a patient with early signs of respiratory fail-
ure (e.g., desaturation within 1 h from extubation) but no 
pre-defined risk factors might be regarded as more at risk 
than a patient presenting only some pre-extubation risk 
factors. Fourth, HFNC was arbitrarily implemented for 
24 h only, while in everyday clinical practice, its discontin-
uation would more likely be based on the patient’s clini-
cal evolution. Fifth, no physiologic test was performed to 
guide randomization (i.e., predictive enrichment: HFNC 
could have been implemented only in patients who have 
decreased respiratory rate after 30  min of treatment). 
Finally, patients developing hypercapnia during the SBT 
were excluded; thus, findings from this study do not apply 
to this population, which might be the most clinically rel-
evant [5] and should be considered as post-extubation 
NIV application. Despite these limitations, we must rec-
ognize that study findings on the role of HFNC in the 
post-extubation period are relevant and encouraging: 
Incidence of respiratory failure reflected the hypothesized 
reduction granted by HFNC and re-intubation somehow 
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decreased, too. Mortality and length of stay were low 
and similar in both groups. Moreover, the authors per-
formed a multivariate logistic regression analysis to iden-
tify factors independently associated with post-extubation 
respiratory failure. Candidate variables were: HFNC, 
diagnosis of cancer, days on mechanical ventilation before 
enrollment, diagnosis of chronic obstructive pulmonary 
disease (COPD), body mass index (BMI) and heart failure 
as etiology of respiratory failure. The only factor indepen-
dently associated with prevention of respiratory failure 
was HFNC, while diagnosis of cancer increased the risk.
After the switch from invasive mechanical ventila-
tion to unassisted spontaneous breathing, the follow-
ing untoward effects may arise as direct consequence of 
the sudden loss of positive intrathoracic pressure [6]: 
End-expiratory transpulmonary pressure decreases to a 
level that might be below the closing volume of relatively 
unstable alveoli, posing risk of collapse and atelectasis; the 
difference between intravascular capillary pressure and 
alveolar pressure increases, both directly and as a result 
of increase in cardiac output, increasing the risk of alveo-
lar transudation and edema. Moreover, after removal of 
the endotracheal tube, the airway lumen diameter might 
abruptly decrease, especially during inspiratory efforts, 
increasing airway resistance and, at high airflow rates, fur-
ther decreasing alveolar pressure and increasing the work 
of breathing. These phenomena might initiate a vicious 
circle that leads to worsened oxygenation and increased 
hypoxic drive, inspiratory effort and consequently 
transpulmonary pressure. Heterogeneity of the lung 
parenchyma due to atelectasis could lead to extremely ele-
vated regional driving transpulmonary pressure, further 
worsening lung injury and edema. The physiologic effects 
of HFNC might perfectly match the patient need during 
the post-extubation period [7–9]. HFNC generates a “pos-
itive end-expiratory pressure (PEEP) effect” that might 
increase end-expiratory transpulmonary pressure stabi-
lizing the alveoli, increase alveolar pressure decreasing 
the hydrostatic capillary-alveolar gradient and increase 
the airways caliber. Moreover, HFNC improves oxygena-
tion and  CO2 clearance, thus decreasing the hypoxic and 
hypercapnic drives and the inspiratory effort. In this way, 
driving transpulmonary pressure decreases, preventing 
further injury, and work of breathing is reduced, prevent-
ing fatigue [10]. Finally, heated humidified gas delivered 
by HFNC can promote secretions fluidity and clearance. 
These data suggest that HFNC could effectively contribute 
to interrupt the post-extubation vicious circle of edema, 
excessive effort, lung injury and muscle fatigue, facilitat-
ing full recovery of lung function.
In conclusion, as described by the study of Dr. Fer-
nandez and colleagues [2], HFNC might be a powerful 
respiratory support in the post-extubation period with 
multiple physiologic and clinical benefits. However, 
use of HFNC should be limited to patients at risk of re-
intubation, while NIV should be considered promptly in 
COPD patients and in those with rapid deterioration of 
the respiratory function while on HFNC.
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